Physician profile
Jess Arcure
NPI 1700100351
$1,489.68
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,362 · 2020: $75.75 · 2022: $52.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $336.26 | 2019 | |
| Zyla Life Sciences, INC. | $314.80 | 2019 | |
| Daiichi Sankyo INC. | $165.99 | 2019 | |
| Medtronic USA, INC. | $115.70 | 2019-2020 | |
| Boston Scientific Corporation | $84.82 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $80.77 | 2019 | |
| Scilex Pharmaceuticals INC. | $76.55 | 2019 | |
| Allergan, INC. | $70.15 | 2019 | |
| Mdd US Operations, LLC | $49.59 | 2019 | |
| Pfizer INC. | $37.10 | 2019 | |
| Horizon Therapeutics Plc | $29.07 | 2019 | |
| Titan Pharmaceuticals, INC. | $25.03 | 2019 | |
| Indivior INC. | $21.20 | 2019 | |
| Sentynl Therapeutics, INC. | $18.29 | 2019 | |
| Dynasplint Systems INC. | $17.10 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $16.27 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.98 | 2022 | |
| Assertio Therapeutics, INC. | $15.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jess Arcure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.